相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
Chun-Yu Liu et al.
CANCER (2008)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
M. Koopman et al.
ANNALS OF ONCOLOGY (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacogenetics of irinotecan metabolism and transport: An update
NF Smith et al.
TOXICOLOGY IN VITRO (2006)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
T Lecomte et al.
CLINICAL CANCER RESEARCH (2004)
ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition
FA de Jong et al.
CLINICAL CANCER RESEARCH (2004)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
L Paoluzzi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
New options and old dilemmas in the treatment of patients with advanced colorectal cancer
CJA Punt
ANNALS OF ONCOLOGY (2004)
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels
MV Mandola et al.
PHARMACOGENETICS (2004)
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
M Ychou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan
Y Ando et al.
THERAPEUTIC DRUG MONITORING (2002)
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
I Cascorbi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
